Traditionally, the cognitive decline associated with AD was attributed to the accumulation of amyloid and tau but emerging evidence suggests that neuroinflammation driven by and triggering additional Nlrp3 inflammasome activation is another critical contributor to AD pathology. This evidence concerns the gene MAPT and Alzheimer disease.